Artiva Biotherapeutics, Inc.(ARTV) - 2025 Q2 - Quarterly Results

Business and Clinical Highlights Artiva advanced AlloNK® in autoimmune diseases, initiating a global basket trial and expanding US enrollment - The first patient has been treated in a global basket trial exploring AlloNK® combined with rituximab for refractory rheumatoid arthritis (RA), Sjögren's disease (SjD), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc)[1][6] - Over a dozen patients have been treated with AlloNK® plus a monoclonal antibody (mAb) across various autoimmune diseases in both company-sponsored and investigator-initiated trials[1][2][6] - More than a dozen clinical sites are actively enrolling patients across two company-sponsored trials in the US for autoimmune diseases, including a Phase 2a basket trial and a Phase 1/1b trial in systemic lupus erythematosus (SLE)[2][6] - The company anticipates that its therapy, including the use of cyclophosphamide and fludarabine, can be administered and managed in an outpatient setting[2] Upcoming Milestones Artiva expects initial AlloNK® safety data by year-end 2025, with lead indication and clinical response data in 1H 2026 - By Year-End 2025: The company plans to present initial safety and translational data for AlloNK® + mAb, provide insights into its tolerability in community rheumatology sites, and disclose the lead indication for further development[1][2][6] - 1H 2026: Artiva expects to present initial clinical response data in the selected lead autoimmune indication, which will inform the registrational strategy[1][6] Second Quarter 2025 Financial Results Artiva reported a $21.3 million net loss in Q2 2025, with $142.4 million cash providing runway into Q2 2027 Financial Performance Summary Artiva's Q2 2025 showed $142.4 million cash, increased operating expenses, and a $21.3 million net loss - As of June 30, 2025, the company had cash, cash equivalents, and investments of $142.4 million, which is expected to fund operations into Q2 2027[1][10] Q2 2025 Financial Highlights (vs. Q2 2024) | Financial Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Research and Development Expenses | $17.9 million | $12.3 million | | General and Administrative Expenses | $4.9 million | $3.9 million | | Other Income (expense), net | $1.6 million | ($1.7 million) | | Net Loss | ($21.3 million) | ($17.8 million) | Condensed Balance Sheets Total assets decreased to $169.4 million by June 30, 2025, from $209.6 million at year-end 2024, due to reduced cash Condensed Balance Sheet Data (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Assets | | | | Cash, cash equivalents and investments | $142,365 | $185,428 | | Total assets | $169,391 | $209,581 | | Liabilities & Equity | | | | Total liabilities | $20,350 | $22,940 | | Stockholders' equity | $149,041 | $186,641 | | Total liabilities and stockholders' equity | $169,391 | $209,581 | Condensed Statements of Operations Artiva reported a net loss of $21.3 million (or ($0.87) per share) for Q2 2025, due to higher R&D expenses Statement of Operations Highlights (in thousands, except per share data) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Research and development | $17,861 | $12,333 | | Total operating expenses | $22,810 | $16,190 | | Loss from operations | ($22,810) | ($16,190) | | Net loss | ($21,254) | ($17,843) | | Net loss per share | ($0.87) | ($22.00) | About Artiva Biotherapeutics Artiva Biotherapeutics is a clinical-stage biotech developing accessible cell therapies for autoimmune diseases and cancers, with AlloNK® as its lead - Artiva's mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers[7] - The lead program, AlloNK® (AB-101), is an allogeneic, off-the-shelf, non-genetically modified NK cell therapy candidate currently being evaluated in three clinical trials for B-cell driven autoimmune diseases[7]